Oxurion Valuation

Is TG40 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of TG40 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate TG40's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate TG40's fair value for valuation analysis.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for TG40?

Key metric: As TG40 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for TG40. This is calculated by dividing TG40's market cap by their current revenue.
What is TG40's PS Ratio?
PS Ratio4.5x
Sales€84.00k
Market Cap€374.15k

Price to Sales Ratio vs Peers

How does TG40's PS Ratio compare to its peers?

The above table shows the PS ratio for TG40 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average4x
BPXA Bellicum Pharmaceuticals
0.5xn/a€772.4k
ECX Epigenomics
11.6xn/a€1.1m
SBH Sangui Biotech International
3.8xn/a€419.8k
PA8K Paion
0.003xn/a€44.2k
TG40 Oxurion
4.5xn/a€374.2k

Price-To-Sales vs Peers: TG40 is expensive based on its Price-To-Sales Ratio (4.5x) compared to the peer average (4x).


Price to Sales Ratio vs Industry

How does TG40's PS Ratio compare vs other companies in the DE Biotechs Industry?

6 CompaniesPrice / SalesEstimated GrowthMarket Cap
CNW co.don
0.7xn/aUS$6.97m
V9Z Aceragen
0.4xn/aUS$3.12m
PA8 Paion
0.2x30.2%US$2.78m
V9Z Aceragen
0.3x-161.8%US$2.18m
TG40 4.5xIndustry Avg. 8.0xNo. of Companies6PS0612182430+
6 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: TG40 is good value based on its Price-To-Sales Ratio (4.5x) compared to the European Biotechs industry average (8x).


Price to Sales Ratio vs Fair Ratio

What is TG40's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

TG40 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio4.5x
Fair PS Ration/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate TG40's Price-To-Sales Fair Ratio for valuation analysis.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.


Discover undervalued companies